// App-Quantinova.ai

: Daratumumab in Combination with Vincristine or Nelarabine As Effective Salvage Therapy for Patients with Acute Lymphoblastic Leukemia at High Risk of Relapse

Researchers

Presenter

  • Yishai Ofran

Principal Investigators

  • Chezi Ganzel

  • Shimrit Harlev

  • Ilana Slouzkey

  • Ofrat Beyar Katz

  • Michal Hayun

  • Mira Kharit

  • Jacob M. Rowe

  • Avraham Frisch

Medical Centers

  • Bruce Rappapport Faculty of Medicine, Technion Israeli Institute of Technology, Haifa, Israel

  • Department of Hematology and Bone Marrow Transplantation, Rambam Health Care Campus, Haifa, Israel

  • Department of Hematology, Shaare Zedek Medical Center, Jerusalem, Israel

  • Department of Hematology and Bone Marrow Transplantation, Rambam Health Care Campus, Haifa, Israel

  • Rambam Health Care Campus, Haifa, Israel

Locations

  • Israel

Companies

  • N/A

Study Components

Therapeutic Area

  • Oncology (ONC)

  • Blood/haematological Diseases

  • Genetic Disorder

  • Autoimmune (AI)

Disease

  • Acute lymphoblastic leukemia

  • Graft-versus-host disease

  • Lymphomas

  • Multiple Myeloma

  • B-cell acute lymphoblastic leukemia

  • T-cell acute lymphoblastic leukemia

  • Scott syndrome

Biomarkers

  • Abelson murine leukemia viral oncogene homolog

  • N-Acylethanolamine acid amidase

  • Breakpoint Cluster Region

  • Cluster of Differentiation 19

  • White Blood Cell

Drug/Treatment

  • Gemtuzumab ozogamicin

  • Methotrexate

  • Mitoxantrone

  • daratumumab Intravenous

  • Vincristine

  • Bortezomib

  • Cytarabine liposomal

  • Nelarabine

  • Ponatinib

  • Allopurinol

Outcome

  • N/A

Study Design

  • N/A

Phase

  • NA

Study Id's

  • N/A

Sponsors

  • N/A

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved